Last $0.0004 USD
Change Today 0.00 / 0.00%
Volume 0.0
NUXP On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

nurx pharmaceuticals inc (NUXP) Snapshot

Open
$0.0004
Previous Close
$0.0004
Day High
$0.0004
Day Low
$0.0004
52 Week High
11/26/13 - $0.0006
52 Week Low
12/9/13 - $0.0003
Market Cap
9.4K
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
23.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NURX PHARMACEUTICALS INC (NUXP)

Related News

No related news articles were found.

nurx pharmaceuticals inc (NUXP) Related Businessweek News

No Related Businessweek News Found

nurx pharmaceuticals inc (NUXP) Details

NuRx Pharmaceuticals, Inc., a development stage company, focuses on nuclear receptor target therapeutics for the treatment of cancer. The company’s lead compound, NRX 5183 is in the phase II clinical trial for the treatment of Relapsed Acute Promyelocytic Leukemia. It has a license agreement with Vitae Pharmaceuticals, Inc. to license certain compounds and nuclear receptor technology for human and veterinary use. The company has a joint venture agreement with QuantRX Biomedical Corporation to commercialize point-of-care products. It was formerly known as Quest Group International, Inc. and changed its name to NuRx Pharmaceuticals, Inc. in October, 2007 as a result of business focus shift. The company was founded in 2001 and is based in Irvine, California.

3 Employees
Last Reported Date: 12/29/09
Founded in 2001

nurx pharmaceuticals inc (NUXP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nurx pharmaceuticals inc (NUXP) Key Developments

SEC Revokes Registration Of Registered Securities Of NuRx Pharmaceuticals

An Administrative Law Judge has issued an Initial Decision of Default as to NuRx Pharmaceuticals, Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearings On Registration Suspension Or Revocation Against NuRx Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of NuRx Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUXP:US $0.00 USD 0.00

NUXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NUXP.
View Industry Companies
 

Industry Analysis

NUXP

Industry Average

Valuation NUXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NURX PHARMACEUTICALS INC, please visit www.nurxpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.